The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival
2016 · Nature Communications · 107 citations
https://doi.org/10.1038/ncomms10258
N
Naoya Mimura
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
234
Papers
3.3K
Citations
31
h-index
56
i10-index
Naoya Mimura is an academic researcher from Chiba University Hospital. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Histone Deacetylase Inhibitors Research & Protein Degradation and Inhibitors. The author has an h-index of 31, co-authored 199 publications.
ORCID: 0000-0002-1717-9428Papers by this author
worksRational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
2015 · Blood Cancer Journal · 63 citations
https://doi.org/10.1038/bcj.2015.38
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
2021 · Scientific Reports · 40 citations
https://doi.org/10.1038/s41598-021-00889-0
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
2014 · Leukemia · 33 citations
https://doi.org/10.1038/leu.2014.300
A case of reversible cerebral vasoconstriction syndrome associated with anti-phospholipid antibody syndrome and systemic lupus erythematosus
2021 · eNeurologicalSci · 13 citations
https://doi.org/10.1016/j.ensci.2021.100351
UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease
2023 · Leukemia · 4 citations
https://doi.org/10.1038/s41375-023-01928-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat